Target Name: VPS13A
NCBI ID: G23230
Other Name(s): KIAA0986 | VPS13A variant B | vacuolar protein sorting 13A | Chorein | bridge-like lipid transfer protein family member 5A | VPS13A variant D | Intermembrane lipid transfer protein VPS13A (isoform B) | Intermembrane lipid transfer protein VPS13A | Vacuolar protein sorting 13A | Vacuolar protein sorting 13 homolog A, transcript variant B | Vacuolar protein sorting 13 homolog A, transcript variant A | FLJ42030 | CHAC | VPS13A variant A | Vacuolar protein sorting 13 homolog A, transcript variant D | CHOREIN | VP13A_HUMAN | Chorea-acanthocytosis protein | Intermembrane lipid transfer protein VPS13A (isoform D) | vacuolar protein sorting 13 homolog A | vacuolar protein sorting-associated protein 13A | BLTP5A | chorea-acanthocytosis protein | Intermembrane lipid transfer protein VPS13A (isoform A)

VPS13A: A Protein with A Wide Range of Functions in The Body

VPS13A (KIAA0986) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the KIAA class of proteins, which are known as the K-type ATP-binding proteins. These proteins are involved in the regulation of cellular processes that are essential for the survival and proper functioning of cells.

One of the key functions of VPS13A is its role in the regulation of the sodium channels that are responsible for the flow of electrical signals through nerve and muscle cells. These channels are critical for the proper transmission of signals, which is essential for the function of the nervous system.

In addition to its role in the regulation of sodium channels, VPS13A is also involved in the regulation of the production of new blood vessels, which is critical for the growth and development of tissues. This protein has also been shown to be involved in the regulation of the immune response, which is important for the proper functioning of the body's immune system.

The research on VPS13A is still in its early stages, but it has the potential to be a drug target or biomarker. Several studies have shown that VPS13A is a promising target for new drugs because of its unique structure and the important functions it plays in the body.

One of the key advantages of VPS13A is its expression in a wide range of tissues, which makes it an attractive target for drugs that can affect multiple organs and systems. This can be an important advantage for the development of new treatments for a variety of diseases, such as heart disease, diabetes, and neurodegenerative disorders.

Another advantage of VPS13A is its role in the regulation of the sodium channels. This is an important aspect of the nervous system because these channels are involved in the transmission of electrical signals. Disruptions in the regulation of these channels can lead to a variety of neurological symptoms, including muscle weakness, paralysis, and altered moods.

VPS13A is also involved in the regulation of the production of new blood vessels, which is critical for the growth and development of tissues. This is important for the development and maintenance of tissues, including the brain and heart.

In addition to its functions in the regulation of sodium channels and blood vessel production, VPS13A has also been shown to be involved in the regulation of the immune response. This is important for the proper functioning of the body's immune system, which is critical for the prevention of infection and disease.

Overall, VPS13A is a protein that has a wide range of functions in the body. Its unique structure and its expression in various tissues make it an attractive target for drugs that can affect multiple organs and systems. Further research is needed to fully understand the role of VPS13A in the regulation of cellular processes and to develop new treatments for a variety of diseases.

Protein Name: Vacuolar Protein Sorting 13 Homolog A

Functions: Mediates the transfer of lipids between membranes at organelle contact sites (By similarity). Binds phospholipids (PubMed:34830155). Required for the formation or stabilization of ER-mitochondria contact sites which enable transfer of lipids between the ER and mitochondria (PubMed:30741634). Negatively regulates lipid droplet size and motility (PubMed:30741634). Required for efficient lysosomal protein degradation (PubMed:30709847)

More Common Targets

VPS13A-AS1 | VPS13B | VPS13C | VPS13C-DT | VPS13D | VPS16 | VPS18 | VPS25 | VPS26A | VPS26AP1 | VPS26B | VPS26C | VPS28 | VPS29 | VPS33A | VPS33B | VPS35 | VPS35L | VPS36 | VPS37A | VPS37B | VPS37C | VPS37D | VPS39 | VPS41 | VPS45 | VPS4A | VPS4B | VPS50 | VPS51 | VPS51P8 | VPS52 | VPS53 | VPS54 | VPS72 | VPS8 | VPS9D1 | VPS9D1-AS1 | VRK1 | VRK2 | VRK3 | VRTN | VSIG1 | VSIG10 | VSIG10L | VSIG10L2 | VSIG2 | VSIG4 | VSIG8 | VSIR | VSNL1 | VSTM1 | VSTM2A | VSTM2A-OT1 | VSTM2B | VSTM2B-DT | VSTM2L | VSTM4 | VSTM5 | VSX1 | VSX2 | VTA1 | VTCN1 | VTI1A | VTI1B | VTN | VTRNA1-1 | VTRNA1-2 | VTRNA1-3 | VTRNA2-1 | VTRNA3-1P | VWA1 | VWA2 | VWA3A | VWA3B | VWA5A | VWA5B1 | VWA5B2 | VWA7 | VWA8 | VWC2 | VWC2L | VWCE | VWDE | VWF | VXN | WAC | WAC-AS1 | WAKMAR1 | WAKMAR2 | WAPL | WARS1 | WARS2 | WARS2-AS1 | WAS | WASF1 | WASF2 | WASF3 | WASF4P | WASF5P